The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Assessment of Tocilizumab (Anti–Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients
Open accessAbstract
Extending the functional integrity of renal allografts is the primary goal of transplant medicine. The development of donor-specific antibodies (DSAs) posttransplantation leads to chronic active antibody-mediated rejection (cAMR) and transplant glomerulopathy (TG), resulting in the majority of graft losses that occur in the United States. This reduces the quality and length of life for patients and increases cost. There are no approved treatments for cAMR. Evidence suggests the proinflammatory cytokine interleukin 6 (IL-6) may play an important role in DSA generation and cAMR. We identified 36 renal transplant patients with cAMR plus DSAs and TG who failed standard of care treatment with IVIg plus rituximab with or without plasma exchange. Patients were offered rescue therapy with the anti-IL-6 receptor monoclonal tocilizumab with monthly infusions and monitored for DSAs and long-term outcomes. Tocilizumab-treated patients demonstrated graft survival and patient survival rates of 80% and 91% at 6 years, respectively. Significant reductions in DSAs and stabilization of renal function were seen at 2 years. No significant adverse events or severe adverse events were seen. Tocilizumab provides good long-term outcomes for patients with cAMR and TG, especially compared with historical published treatments. Inhibition of the IL-6-IL-6 receptor pathway may represent a novel approach to stabilize allograft function and extend patient lives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Sellarés, J., de Freitas, D. G., Mengel, M., Reeve, J., Einecke, G., Sis, B., Hidalgo, L. G., Famulski, K., Matas, A., & Halloran, P. F. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03840.x · Cited by 1,590
Haas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350
Self-citationSolez, K., Colvin, R., Racusen, L., Sis, B., Halloran, P., Birk, P., Campbell, P., Cascalho, M., Collins, A., Demetris, A., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01688.x · Cited by 1,082
Self-citationRituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692
Self-citationDesensitization in HLA-Incompatible Kidney Recipients and Survival
Montgomery, R. A., Lonze, B. E., King, K. E., Kraus, E. S., Kucirka, L. M., Locke, J. E., Warren, D. S., Simpkins, C. E., Dagher, N. N., Singer, A. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012376 · Cited by 687
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
Barr, T. A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., Fan, B., O’Connor, R. A., Anderton, S. M., Bar-Or, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111675 · Cited by 649
Antibody-Mediated Renal Allograft Rejection: Diagnosis and Pathogenesis
Colvin, R. B. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010073 · Cited by 517
Jordan, S. C., Tyan, D., Stablein, D., McIntosh, M., Rose, S., Vo, A., Toyoda, M., Davis, C., Shapiro, R., Adey, D., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000145878.92906.9f · Cited by 435
Self-citation
Cited by
Akhmerov, A., & Marbán, E. (2020) · Circulation Research · doi:10.1161/circresaha.120.317055 · Cited by 693
Long-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 645
Self-citationAntibody-Mediated Rejection of Solid-Organ Allografts
Loupy, A., & Lefaucheur, C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1802677 · Cited by 549
Self-citationA Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
Eskandary, F., Regele, H., Baumann, L., Bond, G., Kozakowski, N., Wahrmann, M., Hidalgo, L. G., Haslacher, H., Kaltenecker, C. C., Aretin, M.-B., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017070818 · Cited by 306
Metadata
- Authors
- Choi, J., Aubert, O., Vo, A., Loupy, A., Haas, M., Puliyanda, D., Kim, I., Louie, S., Kang, A., Peng, A., Kahwaji, J., Reinsmoen, N., Toyoda, M., & Jordan, S. C.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 17
- Issue
- 9
- Pages
- 2381-2389
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W2588200867
- Cited by
- 355
- References
- 32
- FWCI
- 31.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of Tocilizumab (Anti–Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. https://app.cochat.ai/papers/10.1111/ajt.14228
- The paper
- Choi, J., Aubert, O., Vo, A., Loupy, A., Haas, M., Puliyanda, D., Kim, I., Louie, S., Kang, A., Peng, A., Kahwaji, J., Reinsmoen, N., Toyoda, M., & Jordan, S. C. (2017). Assessment of Tocilizumab (Anti–Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. American Journal of Transplantation. https://doi.org/10.1111/ajt.14228
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.